| Field | Specification |
|---|---|
| Target | |
| Alternative names | Thymocyte selection-associated high mobility group box protein TOX; Thymus high mobility group box protein TOX; TOX; KIAA0808 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human TOX recombinant protein (Position: M1-S495). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes thymocyte selection-associated high mobility group box protein TOX in human and mouse samples and is validated for Western blot, IHC, flow cytometry and ELISA. The predicted molecular weight is 57.5 kDa, and the supplier reports an observed band at about 57 kDa.
TOX is a transcriptional regulator with a high mobility group (HMG) box that binds DNA and may alter chromatin structure. It is needed for the development of CD4+ T cells, NK cells and lymphoid tissue, and it is a key driver of the exhausted state of CD8+ T cells in chronic infection and cancer, making it a focus of T-cell exhaustion research.
| Target | Thymocyte selection-associated high mobility group box protein TOX (gene TOX; UniProt O94900, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 57.5 kDa |
| Observed MW | 57 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human, Mouse) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human Jurkat cells, human Ramos cells, human HL-60 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human intestinal cancer tissue, mouse lymphaden tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with a confirmed signal (flow cytometry): HL-60 cells.
Immunogen
Recombinant human TOX fragment (Met1–Ser495), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human and mouse. UniProt places thymocyte selection-associated high mobility group box protein TOX in the nucleus. Tissue expression noted by UniProt (human): Expressed in NK cells. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Xin Cheng et al. (2026) TGF-β inhibition enhances anti-tumor immunity and sensitizes PD-1 blockade therapy of bone marrow-derived myofibroblasts-induced "immunotherapy resistance" tumor model. Cancer Immunology Immunotherapy. 10.1007/s00262-026-04428-6
